Prices delayed by at least 15 minutes | Print


Sareum Holdings PLC (SAR)

ORD GBP 0.0125
Sell: 10.5p|Buy: 11.5p|Change: 3.60 (-24.83%)

Open 

12p


Previous close 

14.5p


Trade high 

12.2p


Volume 

5,990,101


Year high 

149.00p


Year low 

10.00p


Dividend yield 

-


Market capitalisation 

£7.86 mn


P/E ratio 

-


ISIN 

GB00BMC3RJ87


This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment

Share price

Performance 27/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Sareum Holdings PLC 0.00
FTSE AIM All Share+ 0.35
More...

Company profile

Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue (£)
28/03/202401:25:4310.914215.48
28/03/202401:25:2610.9527,1412,971.94
28/03/202401:18:5310.957,000766.50
28/03/202401:18:091210,8001,296.00
28/03/202401:17:041210,0001,200.00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.